巨人症治疗市场－全球产业规模、份额、趋势、机会及预测（按药物、给药途径、分销管道、地区和竞争格局划分，2021-2031年）

全球肢端肥大症治疗市场预计将从 2025 年的 17.2 亿美元成长到 2031 年的 25.7 亿美元，复合年增长率为 6.92%。

该市场涵盖药物、放射学和外科手术干预（特别是生长抑制素类似物和生长激素受体拮抗剂），旨在调节脑下垂体腺瘤引起的荷尔蒙过度分泌。成长的主要驱动力是先进治疗方案的推出，这些方案提高了患者的依从性，并且由于筛检技术的改进，诊断率也随之提高。根据2025年内分泌学会的数据，肢端肥大症患者罹患白血病或淋巴瘤的风险比一般人高3.3倍，显示有效的疾病管理对于预防严重併发症至关重要。

然而，终身药物治疗的高昂费用仍然是市场扩张的主要障碍，限制了医疗资源匮乏地区病患的就医途径。这些必不可少的长期治疗所带来的经济负担，使得许多患者难以获得持续的治疗。因此，这些经济限制限制了全球市场的潜在收益，尤其是在发展中地区，因为这些地区的资金筹措框架无法支持如此昂贵的长期治疗方案。

市场驱动因素

新型口服和长效疗法的商业化正在重塑全球肢端肥大症治疗市场，解决了长期注射治疗的难题。製药公司正优先开发非胜肽口服製剂和缓释注射剂，以提高患者的生活品质和依从性，并有效减轻终身治疗的后勤负担。这种以患者为中心的创新趋势得到了临床试验高保留率的支持。例如，在2025年7月举行的ENDO 2025会议上，Crinetics Pharmaceuticals公司报告称，PATHFNDR-2试验中97.2%的受试者选择继续服用口服药物帕妥昔汀，这表明患者对非侵入性治疗方法的需求十分强劲。

同时，先进生物标记和诊断成像技术的广泛应用使得早期检测和适当干预成为可能，从而推动了市场成长。专科内分泌中心强化筛检通讯协定，识别出更多先前未确诊的患者，并促使标靶治疗处方量增加。这一趋势也反映在主要企业的财务表现中。 Recodati在2025年2月发布的「2024财年初步表现」中预测，其内分泌部门的营收将成长32.8%，达到3.217亿欧元。此外，该公司报告称，其罕见疾病部门在2025财年上半年的营收年增29.2%，显示该领域持续保持成长动能。

市场挑战

终身药物治疗的高昂费用是全球肢端肥大症治疗市场成长的主要障碍。生长抑制素类似物和生长激素受体拮抗剂是疾病控制的关键药物，但其高昂的价格造成了严重的用药障碍。这些治疗方法属于维持治疗而非根治性治疗，需要长期用药，由此产生的累积经济负担对许多医疗预算而言难以承受。高昂的费用直接限制了发展中地区的市场渗透率，因为这些地区的健保体係不足以涵盖昂贵且长期的治疗费用。

此外，即使在有完善保险体系的市场中，经济负担也往往转嫁到病人身上，导致用药依从性差，甚至中断治疗。 2025年，HealthWell基金会报告称，肢端肥大症患者平均每年需要使用2,200美元的津贴来弥补自付费用的差额。这些数据凸显了患者面临的巨大经济负担，这直接阻碍了他们坚持用药。因此，经济拮据使得许多确诊患者无法获得或继续接受必要的治疗，也阻​​碍了市场充分发挥其获利潜力。

市场趋势

学名药进入肢端肥大症治疗领域，从根本上改变了竞争格局，打破了品牌生长抑制素类似物长期以来的价格障碍。随着关键生物製剂专利的到期，製造商正在推出复杂、低成本且生物等效的非专利药製剂，扩大了先前受报销限制的患者获得治疗的机会。这些高性价比替代药物的涌入正在迅速蚕食品牌药的市场份额。根据梯瓦製药公司预测，截至2025年1月，其美国学名药业务预计将在2024年成长15%，这主要得益于首个SandostatinLAR缓释学名药的上市。

同时，以患者为中心的自我给药装置的整合正在革新疾病管理，将治疗从医疗机构转移到患者家中。研发人员将缓释製剂与先进的给药技术（例如预填充自动注射器）结合，以避免医护人员进行侵入性注射。这一趋势减轻了患者频繁就诊和相关疼痛的负担，同时提高了用药依从性和患者的自主性。作为这项进展的象征，Camulus公司在2026年1月的新闻稿中宣布，其每月一次的皮下注射Octreotide製剂Ocryse（用于自我给药）已于2025年在欧盟和英国获得上市核准。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球巨人症治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 药物治疗（生长抑制素类似物、生长激素受体拮抗剂、多巴胺促效剂、联合治疗）
  • 给药途径（口服、皮下注射、其他）
  • 按分销管道（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美巨人症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲巨人症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区巨人症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲巨人症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲巨人症治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球巨人症治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Recordati SpA
• Pfizer Inc.
• Validus Pharmaceuticals LLC
• Ipsen SA
• Crinetics Pharmaceuticals, Inc.
• Amryt Pharma plc
• Debiopharm International SA
• ADVANZ PHARMA CORP.
• Novartis Pharmaceuticals Corporation
• Amolyt Pharma SAS

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Acromegaly Treatment Market is projected to expand from USD 1.72 Billion in 2025 to USD 2.57 Billion by 2031, registering a CAGR of 6.92%. This market includes pharmacological, radiological, and surgical interventions-specifically somatostatin analogs and growth hormone receptor antagonists-aimed at regulating hormonal hypersecretion typically caused by pituitary adenomas. Growth is primarily fueled by the introduction of advanced therapeutic formulations that improve patient compliance, as well as increased diagnosis rates due to better screening technologies. Data from the Endocrine Society in 2025 indicated that acromegaly patients face a 3.3 times higher risk of leukemia or lymphoma compared to the general population, highlighting the critical need for effective disease management to prevent severe comorbidities.

However, market expansion is significantly hindered by the prohibitive costs of lifelong pharmacological therapy, which limits patient access in regions with inadequate healthcare reimbursement systems. The financial burden of these essential, indefinite treatments restricts the ability of many patients to receive consistent care. Consequently, these economic constraints impede the broader reach and potential revenue realization of the global market, particularly in developing areas where funding frameworks cannot support such expensive, long-term regimens.

Market Driver

The commercialization of novel oral and long-acting therapeutics is reshaping the Global Acromegaly Treatment Market by addressing the challenges of chronic injectable regimens. Pharmaceutical developers are prioritizing non-peptide oral formulations and extended-release injectables to enhance patient quality of life and compliance, effectively reducing the logistical burdens of lifelong therapy. This shift toward patient-centered innovation is supported by strong clinical trial retention; for instance, Crinetics Pharmaceuticals reported at 'ENDO 2025' in July 2025 that 97.2% of eligible participants in the PATHFNDR-2 study chose to continue with the oral drug paltusotine, signaling a robust demand for non-invasive options.

Simultaneously, the widespread adoption of advanced biomarkers and diagnostic imaging is driving market growth by facilitating earlier detection and timely intervention. Enhanced screening protocols in specialized endocrinology centers are identifying previously undiagnosed patients, leading to increased prescription volumes for targeted therapies. This trend is reflected in the financial performance of key players; Recordati's 'Preliminary Results for Full Year 2024' in February 2025 showed a 32.8% revenue increase in their Endocrinology franchise, reaching €321.7 million. Furthermore, Recordati reported that revenue for its Rare Diseases unit grew by 29.2% in the first half of 2025 compared to the prior period, illustrating the sector's sustained momentum.

Market Challenge

The prohibitive cost of lifelong pharmacological therapy represents a major obstacle to the growth of the Global Acromegaly Treatment Market. While somatostatin analogs and growth hormone receptor antagonists are vital for managing the disease, their high pricing creates significant accessibility barriers. Since these interventions are maintenance therapies rather than cures, they require indefinite administration, resulting in a cumulative financial burden that many healthcare budgets cannot sustain. This high cost directly limits market penetration in developing regions where reimbursement frameworks are insufficient to cover such expensive, long-term regimens.

Moreover, even in markets with established insurance systems, the economic strain is frequently shifted to patients, leading to reduced adherence and treatment discontinuation. In 2025, the HealthWell Foundation reported that patients diagnosed with acromegaly utilized an average of $2,200 in annual grant funding specifically to bridge the gap for out-of-pocket expenses. This data underscores the financial toxicity facing patients, which directly hampers the consistent consumption of therapeutics. Consequently, the market struggles to realize its full revenue potential as economic constraints prevent a large portion of the diagnosed population from accessing or maintaining necessary care.

Market Trends

The entry of generic acromegaly therapeutics is fundamentally altering the competitive landscape by dismantling the long-standing price barriers associated with branded somatostatin analogs. As patents for major biologics expire, manufacturers are introducing complex generic formulations that offer bioequivalent efficacy at reduced costs, thereby expanding treatment access for patient populations previously restricted by reimbursement limitations. This influx of cost-effective alternatives is rapidly capturing market share from originator products; according to Teva Pharmaceuticals in January 2025, their U.S. Generics business grew by 15% in 2024, a performance significantly bolstered by the launch of the first generic version of Sandostatin LAR Depot.

Concurrently, the integration of patient-centric self-administration devices is revolutionizing disease management by shifting care from clinical settings to the patient's home. Developers are coupling prolonged-release formulations with advanced delivery technologies, such as pre-filled autoinjectors, to eliminate the need for invasive injections administered by healthcare professionals. This trend addresses the burden of frequent clinic visits and associated pain, enhancing adherence and patient autonomy. Highlighting this progress, Camurus confirmed in a January 2026 press release that its novel once-monthly subcutaneous octreotide depot, Oclaiz, designed for self-administration, received marketing authorization in the European Union and the United Kingdom in 2025.

Key Market Players

• Recordati S.p.A.
• Pfizer Inc.
• Validus Pharmaceuticals LLC
• Ipsen S.A.
• Crinetics Pharmaceuticals, Inc.
• Amryt Pharma plc
• Debiopharm International SA
• ADVANZ PHARMA CORP.
• Novartis Pharmaceuticals Corporation
• Amolyt Pharma SAS

Report Scope

In this report, the Global Acromegaly Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acromegaly Treatment Market, By Drugs

• Somatostatin Analogs
• Growth Hormone Receptor Antagonists
• Dopamine Agonists
• Combination Therapy

Acromegaly Treatment Market, By Route of administration

• Oral
• Subcutaneous
• Others

Acromegaly Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Acromegaly Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acromegaly Treatment Market.

Available Customizations:

Global Acromegaly Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Acromegaly Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drugs (Somatostatin Analogs, Growth Hormone Receptor Antagonists, Dopamine Agonists, Combination Therapy)
  • 5.2.2. By Route of administration (Oral, Subcutaneous, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Acromegaly Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drugs
  • 6.2.2. By Route of administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Acromegaly Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drugs
      • 6.3.1.2.2. By Route of administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Acromegaly Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drugs
      • 6.3.2.2.2. By Route of administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Acromegaly Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drugs
      • 6.3.3.2.2. By Route of administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Acromegaly Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drugs
  • 7.2.2. By Route of administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Acromegaly Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drugs
      • 7.3.1.2.2. By Route of administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Acromegaly Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drugs
      • 7.3.2.2.2. By Route of administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Acromegaly Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drugs
      • 7.3.3.2.2. By Route of administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Acromegaly Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drugs
      • 7.3.4.2.2. By Route of administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Acromegaly Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drugs
      • 7.3.5.2.2. By Route of administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Acromegaly Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drugs
  • 8.2.2. By Route of administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Acromegaly Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drugs
      • 8.3.1.2.2. By Route of administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Acromegaly Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drugs
      • 8.3.2.2.2. By Route of administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Acromegaly Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drugs
      • 8.3.3.2.2. By Route of administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Acromegaly Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drugs
      • 8.3.4.2.2. By Route of administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Acromegaly Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drugs
      • 8.3.5.2.2. By Route of administration
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Acromegaly Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drugs
  • 9.2.2. By Route of administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Acromegaly Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drugs
      • 9.3.1.2.2. By Route of administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Acromegaly Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drugs
      • 9.3.2.2.2. By Route of administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Acromegaly Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drugs
      • 9.3.3.2.2. By Route of administration
      • 9.3.3.2.3. By Distribution Channel

10. South America Acromegaly Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drugs
  • 10.2.2. By Route of administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Acromegaly Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drugs
      • 10.3.1.2.2. By Route of administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Acromegaly Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drugs
      • 10.3.2.2.2. By Route of administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Acromegaly Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drugs
      • 10.3.3.2.2. By Route of administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Acromegaly Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Recordati S.p.A.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Validus Pharmaceuticals LLC
• 15.4. Ipsen S.A.
• 15.5. Crinetics Pharmaceuticals, Inc.
• 15.6. Amryt Pharma plc
• 15.7. Debiopharm International SA
• 15.8. ADVANZ PHARMA CORP.
• 15.9. Novartis Pharmaceuticals Corporation
• 15.10. Amolyt Pharma SAS

16. Strategic Recommendations

17. About Us & Disclaimer